Condition: Partial-Onset Seizures · Primary Generalized Tonic-clonic Seizures · Sponsor: Eisai Co., Ltd.
The purpose of this study is to determine the safety of Fycompa for injection after administration in participants with epilepsy (partial-onset seizures \[including secondarily generalized seizures\]) (age 4 years or older) or primary generalized tonic-clonic seizures (age 12 years or older).
This description comes directly from the study's public registry record.
Eisai Inquiry Service · 0120-419-497 · eisai-chiken_hotline@hhc.eisai.co.jp
Always discuss trial participation with your own doctor first.
| 1 | Tokyo, Japan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06657378